FY2024 Earnings Forecast for MMSI Issued By Zacks Research

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Stock analysts at Zacks Research increased their FY2024 earnings per share estimates for Merit Medical Systems in a research note issued to investors on Wednesday, November 20th. Zacks Research analyst I. Bandyopadhyay now expects that the medical instruments supplier will post earnings per share of $3.36 for the year, up from their previous forecast of $3.31. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.36 per share. Zacks Research also issued estimates for Merit Medical Systems’ Q3 2025 earnings at $0.93 EPS, Q4 2025 earnings at $0.98 EPS, FY2025 earnings at $3.70 EPS and FY2026 earnings at $4.07 EPS.

Merit Medical Systems (NASDAQ:MMSI) last announced its quarterly earnings data on Wednesday, October 30th. The medical instruments supplier reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.80 by $0.06. Merit Medical Systems had a net margin of 9.05% and a return on equity of 15.61%. The business had revenue of $339.85 million for the quarter, compared to analyst estimates of $334.60 million. During the same period in the prior year, the firm posted $0.75 EPS. The company’s revenue was up 7.8% on a year-over-year basis.

A number of other equities analysts also recently commented on the company. Barrington Research reaffirmed an “outperform” rating and issued a $114.00 price objective on shares of Merit Medical Systems in a research note on Thursday, October 31st. StockNews.com cut shares of Merit Medical Systems from a “buy” rating to a “hold” rating in a research report on Sunday, November 3rd. Bank of America increased their price objective on shares of Merit Medical Systems from $92.00 to $103.00 and gave the stock a “neutral” rating in a research report on Monday, September 16th. Piper Sandler restated an “overweight” rating and set a $110.00 target price (up previously from $100.00) on shares of Merit Medical Systems in a report on Monday, September 9th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $109.00 price target on shares of Merit Medical Systems in a research report on Thursday, October 31st. Three investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $103.36.

Merit Medical Systems Trading Up 0.9 %

Shares of MMSI opened at $105.03 on Friday. Merit Medical Systems has a twelve month low of $65.46 and a twelve month high of $105.46. The firm has a market capitalization of $6.12 billion, a P/E ratio of 51.49, a price-to-earnings-growth ratio of 2.60 and a beta of 0.89. The company has a current ratio of 5.36, a quick ratio of 3.82 and a debt-to-equity ratio of 0.57. The stock’s fifty day simple moving average is $98.23 and its 200 day simple moving average is $90.55.

Insider Activity

In other news, Director F. Ann Millner sold 12,500 shares of Merit Medical Systems stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $101.55, for a total value of $1,269,375.00. Following the completion of the transaction, the director now owns 32,391 shares in the company, valued at approximately $3,289,306.05. This trade represents a 27.85 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Raul Jr. Parra sold 29,646 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $98.02, for a total value of $2,905,900.92. Following the completion of the sale, the chief financial officer now owns 16,361 shares of the company’s stock, valued at $1,603,705.22. This trade represents a 64.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 3.70% of the company’s stock.

Hedge Funds Weigh In On Merit Medical Systems

Large investors have recently bought and sold shares of the business. Opal Wealth Advisors LLC acquired a new position in Merit Medical Systems during the 2nd quarter valued at about $29,000. DekaBank Deutsche Girozentrale bought a new position in Merit Medical Systems in the 1st quarter worth approximately $44,000. USA Financial Formulas acquired a new stake in Merit Medical Systems in the 3rd quarter valued at approximately $59,000. EntryPoint Capital LLC raised its stake in Merit Medical Systems by 2,666.7% during the 1st quarter. EntryPoint Capital LLC now owns 913 shares of the medical instruments supplier’s stock valued at $69,000 after acquiring an additional 880 shares in the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Merit Medical Systems by 142.3% during the second quarter. GAMMA Investing LLC now owns 831 shares of the medical instruments supplier’s stock valued at $71,000 after purchasing an additional 488 shares during the period. Institutional investors own 99.66% of the company’s stock.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.